Shop
eStoreRx™
Online Supplement Dispensary
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional
This inclusive membership contains all of the the tools you need to grow your business, including WholeLifeRx™, Nimativ®, WholeLifeQ™, eStoreRx™ and Practice Success Programs.
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
April 18 2024
Results of a large population-based observational cohort study examining the association between weight loss and diabetes remission were recently publ...
Researchers conducted a double-blind randomized placebo-controlled study, assigning 27 Crohn’s disease (CD) patients in remission to 2000 IU/day of vitamin D3 or placebo for 3 months. They determined intestinal permeability (IP), plasma-cathelicidin (LL-37), human-beta-defensin-2 (hBD2), disease activity [Crohn’s Disease Activity Index (CDAI)], c-reactive protein (CRP), fecal calprotectin, Quality of Life (QoL) and serum vitamin d (25(OH)D) at 0 and 3 months. Results showed that at 3 months, 25(OH)D concentrations were significantly higher in the treated group, and intra-group analysis showed increased LL-37 [an antimicrobial peptide (AMP) of the innate immune system expressed by the gastrointestinal epithelium] concentrations, and maintenance of IP measures. In contrast, in the placebo group, the small bowel and gastro-duodenal permeability increased from baseline. At 3 months, patients with 25(HO)D levels > 75 nmol/L had significantly lower CRP, higher QoL, higher LL-37 concentrations and lower CDAI scores compared to those with lower 25(OH)D levels.
T Raftery, et al. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomized double-blind placebo-controlled study. United Euro Gastro Journal 2015, Vol. 3(3) 294-302
Submit this form and you'll receive our latest news and updates.
*These statements have not been evaluated by the Food and Drug Administration. This product has not intended to diagnose, treat, cure, or prevent any disease.
© 2023 Biotics Research Corporation - All Rights Reserved
Submit your comment